IN the last decade, genome-wide association studies (GWAS) have been the preferential tool to investigate the genetic basis of complex diseases and traits, leading to the identification of an appreciable number of loci (GWAS Catalog; [@bib43]). Soon after the first wave of studies, a pattern emerged: there exists a sizable discrepancy between, on the one hand, the number of loci that are declared significantly associated and the proportion of phenotypic variance they explain ([@bib28]) and, on the other hand, the amount of information that the entire collection of genotyped single nucleotide polymorphisms (SNPs) appears to contain about the trait ([@bib33]; [@bib46]). To increase the number of loci discovered (and their explanatory power), substantial efforts have been made to obtain larger sample sizes by genotyping large cohorts ([@bib26]; UK Biobank, <http://www.ukbiobank.ac.uk>) and by relying on meta-analysis. However, the gap remains, although not as large as in the original reports. This parallels, in part, the discrepancy between the polygenic model that is used to define complex traits and the simple linear-regression approach to the discovery of associated SNPs which is standard practice, as underscored, for example, in [@bib25], [@bib40], and [@bib34]).

Two approaches to bridge the gap emerge quite naturally: (a) an attempt to evaluate the role of genetic variants in the context of multiple linear regression, more closely matching the underlying biology; and (b) relaxing the very stringent significance criteria adopted by GWAS to control the false discovery rate (FDR) ([@bib6]) rather than the family-wise error rate (FWER)---a strategy that has been shown to be attractive when prediction is considered as an end goal together with model selection ([@bib1]). Both strategies have been pursued, but have encountered a mix of successes and challenges.

The use of multiple linear regression for the analysis of GWAS data has been proposed as early as 2008 ([@bib23]; [@bib45]). By examining the distribution of the residuals, it is clear that it provides a more appropriate model for complex traits. However, its use to discover relevant genetic loci has encountered difficulties in terms of computational costs and interpretability of results. On the computational side, progress has been made using approaches based on convex optimization such as the lasso ([@bib49]), developing accurate methods to screen variables ([@bib16]; [@bib44]; [@bib22]), and relying on variational Bayes ([@bib27]; [@bib13]). There are, however, remaining challenges. First, the genetics community is, correctly, very sensitive to the need of replicability, and finite-sample guarantees for the selected variants are sought. Unfortunately, this has been difficult to achieve with techniques such as the lasso: [@bib2] attempt to use stability selection; [@bib48] do a simulation study of a variety of penalized methods, showing that tuning parameters play a crucial role and that standard selection methods for these do not work well; and [@bib19] and [@bib14] propose some analytical approximation of FDR as an alternative to the lasso. Our recent work ([@bib10]) also explores alternative penalty functions that, under some circumstances, guarantee FDR control. Second, multiple linear regression encounters difficulties in dealing with correlated predictors, in that the selection among these is often arbitrary: this is challenging in the context of GWAS, when typically there is a substantial dependence between SNPs in the same genetic region.

The suggestion of controlling FDR rather than FWER in genetic mapping studies that expect to uncover a large number of loci was put forward over a decade ago ([@bib35]; [@bib39]; [@bib9]) and is accepted in the expression quantitative trait loci (eQTL) community, where FDR is the standard error measure. The existence of strong local dependence between SNPs has also posed challenges for FDR-controlling procedures. While the Benjamini--Hochberg procedure (BH) ([@bib6]) might be robust to the correlation between tests that one observes in GWAS, the fact that the same biological association may be reflected in multiple closely located SNPs complicates both the definition and the counting of discoveries, so that it is not immediately evident how FDR should be defined. Prior works ([@bib29]; [@bib5]; [@bib37]) underscore this problem and suggest solutions for specific settings.

This article proposes a phenotype-aware selective strategy to analyze GWAS data which enables precise FDR control and facilitates the application of multiple regression methodology by reducing the dependency between the SNPs included in final testing. The *Methods* section starts by briefly recapitulating the characteristics of GWAS, with reference to an appropriate count of discoveries and the identification of a meaningful FDR to control. We introduce our selective strategy and provide some general conditions under which it controls the target FDR. We then describe a specific selection procedure for GWAS analysis and describe how it can be coupled with standard BH for univariate tests, or with SLOPE ([@bib10]) to fit multiple regression. In the *Results* section, we explore the performance of the proposed methodology with simulations and analyze a data set collected in the study of the genetic basis of blood lipids. In both cases, the FDR-controlling procedures we propose allow us to explain a larger portion of the phenotype variability, without a substantial cost in terms of increased false discoveries.

With this article, we are making available an R package geneSLOPE ([@bib11]) at the Comprehensive R Archive Network (CRAN). The package can analyze data in the PLINK ([@bib32]) format.

Methods {#s1}
=======

The GWAS design, dependence, and definition of discoveries {#s2}
----------------------------------------------------------

The goal of a GWAS study is to identify locations in the genome that harbor variability which influences the phenotype of interest. This is achieved using a sample of *n* individuals, for whom one acquires trait values $y_{i}$ and genotypes at a collection of *M* SNPs that span the genome. Following standard practice, we summarize genotypes by the count of copies of minor alleles that each individual has at each site, resulting in an $n \times M$ matrix *X*, with entries $X_{ij} \in \left\{ {0,1,2} \right\}.$ The variant index *j* is taken to correspond to the order of the position of each SNP in the genome. The true relation between genetic variants and phenotypes can be quite complex. For simplicity, and in agreement with the literature, we assume a linear additive model, which postulates that the phenotype value $y_{i}$ of subject *i* depends linearly on her/his allele counts at an unknown set $C$ of causal variants. Since there is no guarantee *a priori* that the variants in $C$ are part of the genotype set, we indicate their allele counts with $Z_{ij},$ letting$$y_{i} = b_{0} + {\sum\limits_{j \in C}{b_{j}Z_{ij}}} + \mathit{\epsilon}_{i}.$$Investigating the relation between *y* and *X* is helpful to learn information about the set of causal variants $C$ and their effects $b_{j}$ in two ways: (1) it is possible that some of the causal variants are actually genotyped, so that $Z_{ij} = X_{ik}$ for some *k*; and (2) most importantly, the set of *M* genotyped SNPs contains reasonable proxies for the variants in $C.$ To satisfy (2), GWAS are designed to capitalize on the local dependence between variable sites in the genome known as linkage disequilibrium (LD), which originates from the modality of transmission of chromosomes from parents to children, with modest recombination. The set of *M* genotyped SNPs is chosen with some redundancy, so that the correlation between $X_{j}$ and $X_{j + k}$ is expected to be nonzero for *k* in a certain range: this is to ensure that any untyped casual variant $Z_{l}$ will be appreciably correlated with one (or more) of the typed $X_{j}{\prime s}$ that are located in the same genomic region. Any discovered association between a SNP $X_{j}$ and the phenotype *y* is interpreted as an association between *y* and *some variant* in the genomic *neighborhood* of $X_{j}.$ This design has a number of implications for statistical analysis:

1.  Often, the existence of an association between *y* and each typed variant $X_{j}$ is queried via a test statistic $t_{j}$ which is a function of *y* and $X_{j}$ only: these test statistics are "locally" dependent, with consequences for the choice of multiple comparison adjustment, that, for example, might not need to be as stringent as in the case of independence.

2.  When multiple regression models are used to investigate the relation between *y* and *X*, one encounters difficulties due to the correlation between regressors---the choice among which is somewhat arbitrary.

3.  The fact that the true causal variants are not necessarily included among the genotyped SNPs makes the definition of a true/false association nontrivial.

We want to underscore the last point. To be concrete, let us assume the role of each variant $X_{j}$ is examined with $t_{j},$ the *t*-statistic for $H_{0}^{j}:\beta_{j} = 0,$ with $\beta_{j}$ defined in the univariate regression $y_{i} = \alpha + \beta_{j}X_{ij} + \mathit{\epsilon}_{i}.$ Even if none of the *M* genotyped variants are causal, a number of them will have a coefficient $\beta_{j} \neq 0$ in these reduced models; whenever $X_{j}$ is correlated with one of the variants in $C,$ $H_{0}^{j}$ should be rejected. Indeed, simulation studies that investigate the power and global error control of different statistical approaches routinely adopt definitions of "true positive" that account for correlation between the known causal variant and the genotyped SNPs (see [@bib48] for a recent example). At the same time, a rejection of $H_{0}^{j}$ should not be interpreted as evidence of a causal role for $X_{j}:$ in fact, geneticists equate discovery with the identification of a genomic location rather than with the identification of a variant. The rejection of $H_{0}^{j}$ for a number of correlated neighboring SNPs in a GWAS is described in terms of the discovery of one single locus associated with the trait of interest. The number of reported discoveries, then, corresponds to the number of distinct genomic regions (whose variants are uncorrelated) where an association has been established. This discrepancy between the number of rejected hypotheses and the number of discoveries has important implications for FDR-controlling strategies, which have received only a modest attention in the literature. [@bib37] suggest that in situations similar to those of GWAS, neighboring rejections should be grouped and counted as a single rejection and that the global error of interest should be the expected value of the "proportion of clusters that are falsely declared among all declared clusters." This FDR of clusters---a notion first introduced in [@bib5])---is not the error rate controlled by the Benjamini--Hochberg procedure on the *P*-values for the $H_{0}^{j}$ hypotheses. Indeed, because FDR is the expected value of the ratio of the random number of discoveries, its control depends crucially on how one decides to count discoveries. In [@bib30]) we give another example of how controlling FDR for a collection of hypotheses does not extend to controlling FDR for a smaller group hypotheses logically derived from the initial set. Both in the setting described here and in [@bib30]), targeting FWER would have resulted in less surprising behavior; assuring that the probability of rejecting at least one null $H_{0}^{j}$ is smaller than a level α and this would also guarantee that the probability of rejecting at least one null cluster of hypotheses is smaller than α. [@bib37] study a setting that is close to our problem and propose a methodology to control their target FDR by relying on a Poisson process distribution for the number of false discoveries. Here we investigate a different approach, one that is more tightly linked to the GWAS design, is adapted to the variable extent of LD across the genome, and capitalizes on results in selective inference ([@bib4]).

Controlling the FDR of interesting discoveries by selecting hypotheses {#s3}
----------------------------------------------------------------------

The approach we study emerged from our interest in using multiple linear regression to analyze the relation between *y* and *X*, so it is useful to motivate it in this context. Suppose both $X_{j}$ and $X_{j + 1}$ are strongly correlated with the untyped causal variant $Z_{k}.$ When univariate regression is used as the analysis strategy, both the test statistics $t_{j}$ and $t_{j + 1}$ would have large values, resulting in the discovery of this locus. Instead, the marginal *P*-values for each of the coefficients of $X_{j}$ and $X_{j + 1}$ derived from a multiple linear regression model that includes both variables would be nonsignificant, as $X_{j}$ and $X_{j + 1}$ carry roughly the same information and can be substitutes for each other. Model selection strategies would rather arbitrarily result in the inclusion of one or the other regressor, leading to an underestimate of their importance when resampling methods are used to evaluate significance. Using multiple linear regression, one would achieve the best performance if, from the start, only one of $X_{j}$ and $X_{j + 1}$ (the most strongly correlated with *Z~k~*) is included among the possible regressors. A natural strategy is to prune the set of *M*-typed SNPs to obtain a subset of *m* quasi-orthogonal ones and supply these to the model selection procedure of choice. However, this encounters the difficulty that the best proxy for some of the causal variants might have been pruned, resulting in a loss of power. It seems that, ideally, one would select from a group of correlated SNPs the one that has the strongest correlation with the trait to include among the potential regressors. Unfortunately, this initial screening for association would invalidate any guarantees of the model selection strategy, which operates now not on *m* variables, but on *m selected* ones. The emerging literature of selective inference, however, suggests that we might be able to appropriately account for this initial selection step, preserving guarantees on error rate control.

Abstracting from the specifics of multiple regression, consider the setting where a collection $\mathcal{H}$ of *M* hypotheses $H_{0}^{1},\ldots,H_{0}^{M}$ with some redundancy is tested to uncover an underlying structure of interest. The hypotheses in $\mathcal{H}$ can be organized linearly or spatially and are chosen because *a priori* they provide a convenient and general way of probing the structure; however, it is expected that a large portion of these will be true, and that when one $H_{0}^{j}$ is false, a number of neighboring ones would be also false. In the case of GWAS, these clusters of false hypotheses would correspond to markers correlated with causal mutations. Because of the mismatch between $\mathcal{H}$ and the underlying structure, the number of scientifically interesting discoveries does not correspond to the number of rejected $H_{0}^{j}{\prime s,}$ and strategies that control the FDR defined in terms of these might not lead to satisfactory inference. Specifically, as noted in [@bib37]), "a possibly large number of correct rejections at some location can inflate the denominator in the definition of false discovery rate, hence artificially creating a small false discovery rate, and lowering the barrier to possible false detections at distant locations." This problem was recognized already in [@bib29]) and [@bib5]), who introduce the notion of cluster FDR and suggest defining *a priori* clusters of hypotheses corresponding to signals of interest and applying FDR-controlling strategies to hypotheses relative to these clusters. An implicit example of this approach can be found in the eQTL literature. When investigating the genetic basis of variation in gene expression, the authors in [@bib3]) change the unit of inference from SNPs to genes, so as to bypass the redundancy due to many SNPs in the same neighborhood. Here we take a different approach, where "clusters" of hypotheses are defined *after* looking at the data, and used to select a subset of representative hypotheses. Only this subset is then tested with a procedure that accounts for this initial selection.

Formally, let *y* indicate the data used to test the hypotheses in $\mathcal{H}$ and let $\mathcal{S}\left( y \right)$ be a selection procedure that, on the basis of the data, identifies a subset $\mathcal{H}^{s}$ of *s* representative hypotheses. Let $S = \left\{ {i:1 \leq i \leq M\,\&\, H_{0}^{i} \in \mathcal{H}^{s}} \right\}$ be the set of their indexes, so that it is relevant to control the following FDR*~s~*:$$\text{FD}\text{R}_{s} = E\left\lbrack \frac{\sum_{j \in S}{1\left( {H_{0}^{j}\,\text{rejected}} \right)1\left( {H_{0}^{j}\,\text{true}} \right)}}{1 \vee {\sum_{j \in S}{1\left( {H_{0}^{j}\,\text{rejected}} \right)}}} \right\rbrack.$$In other words, the decision of acceptance/rejection is made only for the hypotheses in the selected set and FDR*~s~* is a natural notion of global error rate. Naively, to control $\text{FD}\text{R}_{s} \leq q,$ one might consider applying a BH at level *q* to the *P*-values $p_{\lbrack S\rbrack}$ corresponding to the subset of hypotheses $\mathcal{H}^{s}.$ However, since these have been chosen by looking at the data---so that, for example, it is acceptable to select the most "promising" hypotheses---the naive approach would not guarantee FDR control. Indeed, consider the case where $\mathcal{H}^{s}$ contains only the hypothesis with the smallest *P*-value: BH applied to this subset of one hypothesis would compare its *P*-value with the target rate *q*, thereby ignoring the original multiplicity. It seems clear that we need to "remember" where the selected hypotheses come from: while we might focus on a subset---to avoid scientific repetition---we need to account for the fact that this subset is selected from an original larger pool, which provided us with a larger freedom margin. A solution that emerges quite naturally consists of using a set of increasing *P*-value thresholds (just as in BH), but one whose severity is defined in terms of the original large collection of hypotheses: the smallest *P*-value $p_{{\lbrack S\rbrack}{(1)}}$ for $\mathcal{H}^{s}$ should be compared with ${q/M},$ the second smallest $p_{{\lbrack S\rbrack}{(2)}}$ with ${{2q}/M},$ *etc*. This can be formally stated by requiring the application of BH to the *P*-values $p_{\lbrack S\rbrack}$ targeting the more stringent level ${{q\left| S \right|}/M},$ where the coefficient $\left| S \right|/M$ penalizes for the initial selection. This rule already appears in the literature in slightly different contexts ([@bib8]; [@bib4]) and it is useful for our problem in that the *P*-value thresholds are identical to those implied by BH on $\mathcal{H},$ but the number of hypotheses tested is smaller and the hypotheses are more clearly separated. This prevents the excessive deflation of the BH threshold that results when each true discovery is represented by many rejected hypotheses, and therefore helps to control the number of false discoveries. The following theorem, proven in the Appendix, reassures us that, under some conditions, the rule that we have described not only makes intuitive sense, but indeed guarantees control of $\text{FD}\text{R}_{s} \leq q.$

***Theorem 1*.** *FDR control for selected hypotheses*. Let $\mathcal{S}\left( \mathit{y} \right)$ be a selection procedure, and let $\mathit{R}^{\mathit{S}}$ be the number of rejections derived by applying BH with target ${\mathit{q}\left| \mathit{S} \right|}/\mathit{M}$ on the selected hypotheses $\mathcal{H}^{\mathit{S}}.$ If the *P*-values satisfy the condition of the **p**ositive **r**egression **d**ependence on a **s**ubset (PRDS) ([@bib7]) and the selection procedure is such that $\mathit{R}^{\mathit{S}}\left( {\mathit{p}_{1},\ldots,\mathit{p}_{\mathit{M}}} \right)$ is nonincreasing in each of the *P*-values $\mathit{p}_{\mathit{i}},$ rejecting $\mathit{R}^{\mathit{S}}$ guarantees control of FDR*~s~*.

Two conditions are required for the discussed program to guarantee FDR*~s~* control: (1) The *P*-values have to satisfy the PRDS property; this is a requirement for most of the proofs of FDR control, and---while difficult to verify---it can be loosely interpreted as the requirement of the positive correlation between *P*-values at linked markers, and it is therefore a reasonable assumption in the GWAS setting ([@bib35]). (2) The selection procedure has to be such that if we imagine reducing one of the *P*-values of the original hypotheses, leaving everything else the same, the final number of rejections does not decrease. This is a property that appears very reasonable and that one would intuitively desire in a testing procedure. An example selection procedure that satisfies the assumptions of the theorem is as follows: the hypotheses $\mathcal{H}$ are separated in groups *a priori* and, from each group, $\text{S}\left( \text{Y} \right)$ selects the hypothesis with the smallest associated *P*-value. In the next section, we describe a slightly more complicated selection procedure $\mathcal{S}\left( y \right)$ that appears appropriate for the case of GWAS, and where the separation of hypotheses into groups is data driven. While this procedure does not satisfy the assumption that the number of rejections is *always* a nonincreasing function of the *P*-values, it does do so for an overwhelming proportion of realistic *P*-value configurations, and our extensive simulations studies suggest that its use in the context of Theorem 1 still leads to FDR*~s~* control.

A GWAS selection procedure: phenotype-aware cluster representatives {#s4}
-------------------------------------------------------------------

In the context of genetic association studies, the selection function $S\left( y \right)$ defined in Procedure 1 below and illustrated in [Figure 1](#fig1){ref-type="fig"}, emerges quite naturally. One starts by evaluating the marginal association of each SNP to the phenotype using the *P*-value of the *t*-test for its coefficient in a univariate regression. Then, SNPs with a *P*-value larger than threshold *π* are removed from consideration. The collection of remaining SNPs is further pruned to obtain a selected set $\mathcal{S}$ with low correlation, so that each variant $X_{i} \in \mathcal{S}$ can be equated to a separate discovery. To achieve this, we define clusters of SNPs using their empirical correlation in our sample, starting from the variants with the strongest association to the phenotype, which are selected as cluster representatives.

![Phenotype-aware cluster representatives. The *x*-axis represents the genome, with the locations of genotyped SNPs $X_{i}$ indicated by tick marks. The true causal effect of each position of the genome is indicated in red; there is only one causal variant in this region, between SNPs $X_{6}$ and $X_{7}.$ Solid black circles indicate the value of $\beta_{i},$ coefficient of $X_{i}$ in a linear approximation of the conditional expectation $E\left( {\left. y \right|X_{i}} \right).$ Asterisks mark the estimated ${\hat{\beta}}_{i}{\prime s}$ in the sample. The SNPs $X_{5}$ and $X_{14},$ selected as cluster representatives in this schematic diagram, are indicated in blue.](61fig1){#fig1}

***Procedure 1*.** *Selection function* $\mathcal{S}\left( y \right)$ *to identify cluster representatives*.

*Input:* $\rho \in \left( {0,1} \right),$ $\pi \in \left( {0,1} \right\rbrack.$ *Screen SNPs:*

1.  *Calculate the* *P*-*value for* $H_{0}^{j}:\beta_{j} = 0,$ *with* $\beta_{j}$ *defined in the univariate regression* $y_{i} = \alpha + \beta_{j}X_{ij} + \mathit{\epsilon}_{i},$ *as* *j* *varies across all SNPs*.

2.  *Retain in* $\mathcal{B}$ *only those SNPs whose* *P*-*values are smaller than* *π*.

Cluster SNPs:

1.  *Select the SNP* *j* *in* $\mathcal{B}$ *with the smallest* *P*-*value* *and find all SNPs whose absolute value of the Pearson correlation with this selected SNP* $\left| r \right|$ *are larger than or equal to* *ρ.*

2.  *Define this group as a cluster and SNP* *j* *as the* *representative of the cluster. Include SNP* *j* *in* $\mathcal{S},$ *and remove the entire cluster from* $\mathcal{B}.$

3.  *Repeat steps 3--4 until* $\mathcal{B}$ *is* *empty.*

Procedure 1 has two parameters: *π* and *ρ*, corresponding to the two steps of the selection. The screening in steps 1--2 is similar to that described in [@bib16] and [@bib45]) for model selection procedures, where the parameter *π* controls the stringency of the selection based on univariate association. On the one hand, large values of *π* result in larger cluster sizes, and hence less precise localization. On the other hand, in the context of multiple regression, it is possible to uncover a role for variants that have weak marginal effects due to masking. To enable this, one must not be too stringent in the initial screening step. In all the simulations and data analyses presented here we have used $\pi = 0.05,$ which seems to be a good compromise. The results in [@bib16] and [@bib45]) can provide additional guidance on the choice of *π*.

Steps 3--5 of Procedure 1 aim to "thin" the set of SNPs on account of the dependency among them. This is related to the selection of tag SNPs ([@bib21]), for which there is an extensive literature, and is similar to correlation-reduction approaches ([@bib38]). A defining characteristic of Procedure 1, however, is that both the SNP clusters and their representatives are selected with reference to the phenotype of interest. This ensures that the representatives maximize power, and that the location of the true signal is as close as possible to the center of the respective cluster. This also reduces the probability of the selection of more than one SNP per causal variant.

The parameter *ρ* needs to be chosen to reflect what researchers would consider as independent discoveries. Rather than aggregating discoveries at one locus *a posteriori*, our procedure simply requires specifying *a priori* which level of correlation between two SNPs would result in considering the signals at these two SNPs as indistinguishable. Typically, the researcher's choice would depend on the density of the available markers, sample size, and the expected effect size. We note that as sample size increases, methods based on marginal analysis \[with single-marker tests (SMTs)\] and multivariate linear regression behave differently. When sample or effect size increases, the signal due to one causal variant is detectable at SNPs with decreasing levels of correlation. Therefore, to avoid excessive true discoveries by SMTs, the researcher might want to choose a correspondingly lower value of *ρ*. However, with multiple linear regression, an increase in sample size results in an increase of resolution. This means that with increasing probability only the "best" representative of the causal variant will be selected and a meaningful analysis of the data can be carried out with larger values of *ρ*. We note that this is one advantage of analyzing the data with multiple linear regression rather than relying on marginal tests.

Certainly, Procedure 1 is but one possibility for creating clusters. For example, one might want to include information on physical distance in the formation of clusters. In our experiments, however, this has not led to better performance. On the other hand, we note that clusters cannot be defined using information on physical distance alone: it is the correlation *r* between the SNPs that determines how the signal due to one causal variant leaks across multiple sites. The *Result* section illustrates some of the properties of the clusters derived from Procedure 1.

We now consider two approaches to the analysis of GWAS data that can be adopted in conjunction with the selection of cluster representatives to control the FDR*~s~*.

Univariate testing procedures after selection {#s5}
---------------------------------------------

By and large, the most common approach to the analysis of GWAS data relies on univariate tests of association between trait and variants. This has advantages in terms of computational costs, handling of missing data, and portability of results across studies. We therefore start by considering how to control relevant FDR in this context.

We consider two different approaches to obtain the *P*-values for each of the $H_{0}^{j}$ hypotheses: univariate linear regression (which we indicate with SMT) and EMMAX ([@bib25]), a mixed model that allows us to consider polygenic effects. To enable computational scaling, EMMAX only estimates the parameters of the variance component model once rather than for every marker. We use SMTs and EMMAXs to denote the procedures that consist of testing the set of hypotheses $\mathcal{H}^{s}$ corresponding to cluster representatives, using *P*-values obtained with SMT and EMMAX, respectively, and identifying rejections with the BH*~s~* procedure described below.

***Procedure 2*.** *Benjamini-Hochberg on selected hypotheses BH~s~*.

*Input: M* = *total number of SNPs* (*before initial screening*), $\mathcal{H}^{s}$ = *collection of selected hypotheses* (*cluster representatives*), $q \in \left( {0,1} \right\rbrack$ = *desired level for FDR~s~*.

*Let* $\left| S \right|$ *be the number of hypotheses in* $\mathcal{H}^{s},$ *and* $p_{\lbrack S\rbrack}$ *the vector of their* *P*-*values. Apply BH to* $p_{\lbrack S\rbrack}$ *with target level* ${{\left| S \right|q}/M}.$

GeneSLOPE: FDR control in multiple regression {#s6}
---------------------------------------------

SLOPE ([@bib10]) is a recently introduced extension of the lasso that achieves FDR control on the selection of relevant variables when the design is nearly orthogonal. Specifically, assume the following model:$$Y = X\beta + z,$$where *X* is the design matrix of the dimension $n \times M,$ $z \sim N\left( {0,\sigma^{2}I_{n \times n}} \right)$ is the *n*-dimensional vector of random errors, and *β* is the *M*-dimensional vector of regression coefficients, a significant portion of which is assumed to be zero. For a sequence of nonnegative and nonincreasing numbers $\lambda_{1},\ldots,\lambda_{M},$ the SLOPE estimate of *β* is the solution to a convex optimization problem$$\hat{\beta} = \underset{b \in R^{M}}{\arg\min}\left\{ {\frac{1}{2}\left\| {y - Xb} \right\|^{2} + \sigma{\sum\limits_{i = 1}^{M}{\lambda_{i}\left| b \right|_{(i)}}}} \right\},$$where $\left| b \right|_{(1)} \geq \ldots \geq \left| b \right|_{(M)}$ are sorted absolute values of the coordinates of *b*.

Defining a discovery as every estimated ${\hat{\beta}}_{i} \neq 0,$ and a false discovery as the case where ${\hat{\beta}}_{i} \neq 0$ but the true $\beta_{i} = 0,$ [@bib10] show that with a specific sequence of $\lambda_{i}$ (corresponding to the sequence of decreasing thresholds in BH) the program in (2) controls FDR at a desired level when *X* is orthogonal. Moreover, the modified sequence λ---described in Procedure 4 in the Appendix---has been shown in simulation studies to achieve FDR control when the regressors are nearly independent and the number of nonzero *β*'s is not too large.

Note that, as for other shrinkage methods ([@bib42]; [@bib15]), the results of SLOPE depend on the scaling of explanatory variables: the values of the regularizing sequence in Procedure 4 assume that explanatory variables are "standardized" to have zero mean and a unit $l_{2}$ norm. Moreover, since in most cases the variance of the error term $\sigma^{2}$ is unknown and needs to be estimated, in [@bib10]) an iterative procedure for the joint estimation of *σ* and the vector of regression coefficients was proposed. This is described in the Appendix as Procedure 5, and closely follows the idea of *scaled lasso* ([@bib41]). All these data preprocessing and analysis steps are implemented in R package SLOPE, available on CRAN.

The fact that SLOPE comes with finite-sample guarantees for the selected parameters makes it an attractive procedure for GWAS analysis. However, the presence of substantial dependence between SNPs (regressors *X~j~*) presents challenges: on the one hand, the FDR-controlling properties have only been confirmed so far when the explanatory variables are quasi-independent; and, on the other hand, the definition of FDR is problematic in a setting where the true causal variants are not measured and *X* contains a number of correlated proxies. The identification of a subset of variants with Procedure 1 takes care of both aspects: the regressors are not strongly correlated and they represent different locations in the genome, so that we can expect the projection of the true model in the space they span to be sparse and the number of ${\hat{\beta}}_{i} \neq 0$ to capture the number of scientifically relevant discoveries. We therefore propose, as a potential analysis pipeline, the application of Procedure 1 followed by Procedure 3, which outlines the application of SLOPE to the selected cluster representatives. Both procedures have been implemented in the R package *geneSLOPE*, which is available on CRAN and can handle typical GWAS data provided in PLINK format.

***Procedure 3*.** *geneSLOPE*.

*Input: y* = *vector of trait values*, *M* = *total number of SNPs* (*before initial screening*), $X_{\lbrack S\rbrack}$ = *selected SNPs* (*cluster representatives*), *and* $q \in \left( {0,1} \right\rbrack$ = *desired level for FDR~s~*.

*Initialize* $\mathcal{A} = \varnothing:$

1.  *Center* *y* *by subtracting its mean, and standardize* $X_{\lbrack S\rbrack}$ *so that each column has a zero mean and unit* $l_{2}$ *norm.*

2.  *Calculate the sequence* *λ* *using Procedure 4 and using* *M* *as a total number of regressors, and retain the first* $\left| S \right|$ *elements of it.*

3.  *Compute the residual sum of squares (RSS) obtained* *by regressing* *y* *onto variables in* $e$ *and set* ${\hat{\sigma}}^{2} = {{RSS}/\left( {n - \left| e \right| - 1} \right)},$ *where* $\left| e \right|$ *denotes the cardinality of* $e.$

4.  *Compute the solution* $\hat{\beta}$ *for SLOPE as in Equation 2, explaining* *y* *as a linear function of* $X_{\lbrack S\rbrack}$ *with parameters* $\hat{\sigma}$ *and* *λ*. *Set* $e^{+} = \mathit{supp}\left( \hat{\beta} \right).$

5.  *If* $e^{+} = e$ *stop; if not, set* $e = e^{+}$ *and reiterate steps 3--4*.

Data availability {#s7}
-----------------

To illustrate the performance of our methods, we used the data from the North Finland Birth Cohort (NFBC66) study ([@bib36]), available in the database of Genotypes and Phenotypes (dbGaP) under accession number phs000276.v2.p1 (<http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000276.v2.p1>).

Results {#s8}
=======

To test the performance of the proposed algorithms, we relied on simulations and real data analysis. In both cases, genotype data came from the NFBC66 study ([@bib36]). The raw genotype matrix contains 364,590 markers for 5402 subjects. We filtered the data in PLINK to exclude copy-number variants and SNPs with Hardy--Weinberg equilibrium *P*-value \<0.0001, minor allele frequency \<0.01, or call rate \<95%. This resulted in an $n \times M$ predictor matrix with $n = 5402$ and $M = 334,103.$ When applying GeneSLOPE, missing genotype data were imputed as the SNP mean.

For simulations, the trait values are generated using the multiple regression model:$$Y_{i} = {\sum\limits_{j \in C_{k}}{\beta_{j}{\overset{\sim}{X}}_{ij}}} + \mathit{\epsilon}_{i},i \in \left\{ {1,\ldots,n} \right\}\,,$$where $\overset{\sim}{X}$ is the standardized matrix of genotypes, $C_{k}$ is the set of indices corresponding to "causal" mutations, and $\mathit{\epsilon}_{i} \sim N\left( {0,1} \right).$ The number of causal mutations takes the value $k \in \left\{ {20,50,80,100} \right\},$ and in each replicate the *k* causal features are selected at random from a subset of the *M* SNPs. For each *k*, the values of $\beta_{j}$ are evenly spaced in the interval $\left\lbrack {{SignalMin},SignalMax} \right\rbrack,$ with ${SignalMin}: = 0.6\sqrt{2\text{log}M}$ and ${SignalMax}: = 1.4\sqrt{2\text{log}M}.$ As a result, the smallest genetic effect is rather weak (heritability in a single quantitative trait loci model *h*^2^ = 0.0017), while the strongest effect is relatively large $\left( {h^{2} = 0.0091} \right).$ Each scenario is explored with 100 simulations.

In evaluating FDR*~s~* and power we adopt the following conventions, which we believe to closely mimic the expectations of researchers in this field: the null hypothesis relative to a SNP/cluster representative is true if the SNP/cluster representative has a correlation \<0.3 with any causal variant. Similarly, a causal variant is discovered if at least one of the variants in the rejection set has correlation of at least magnitude 0.3 with it.

In addition to evaluating performance in the context of simulated traits, we apply the proposed procedures to four lipid phenotypes available in NFBC66 ([@bib36]): high-density lipoproteins (HDL), low-density lipoproteins (LDL), triglycerides (TG), and total cholesterol (CHOL). We compare the discoveries obtained by the simple and multiple regression approaches on the NFBC data to those reported in the [@bib20], a much more powerful study based on 188,577 subjects.

Simulation study {#s9}
----------------

### Cluster characteristics: {#s10}

We begin by exploring the distribution of the size of clusters created according to Procedure 1 for two values of $\rho = 0.3,0.5.$ [Figure 2A](#fig2){ref-type="fig"} illustrates the size of clusters when the trait was generated according to the model in Equation 3 with $k = 80$ and genotypes from the NFBC data set. Most of the clusters are rather small and do not include more than five SNPs, and in fact \>50% of them is comprised of one SNP only. [Figure 2B](#fig2){ref-type="fig"} reports the maximal distance in base pairs between the elements of one cluster: apart from the spike at zero (corresponding to clusters with one SNP only), the median distance spanned by clusters is $4.4 \times 10^{4}$ $\left( {2.9 \times 10^{4}} \right)$ for $\rho = 0.3\,\left( 0.5 \right),$ respectively. Of course, differences in the genotype density would result in differences in the cluster sizes obtained.

![(A) Histograms of the number of SNPs included in each cluster when Procedure 1 is applied to *P*-values with $\pi = 0.05$ and $\rho = 0.3$ or $\rho = 0.5.$ (B) Histogram of the maximal distance between SNPs in the same cluster. The symbol "S" on the *x*-axis corresponds to clusters that contain only one SNP.](61fig2){#fig2}

### Error control with EMMAX and SMT: {#s11}

[Figure 3](#fig3){ref-type="fig"} illustrates the results of simulations exploring the FDR*~s~* control properties of BH applied to the complete set of *M* *P*-values obtained from EMMAX or SMT (*i.e.*, with no prescreening or clustering of the hypotheses) and the corresponding two-step approaches we recommend (EMMAXs and SMTs), where cluster representatives are first chosen using Procedure 1 and then discoveries are identified with Procedure 2. The FDR*~s~* for the traditional version of EMMAX and SMT is calculated by mimicking what researchers typically do in practice to interpret GWAS results. Specifically, the SNPs for which the null hypotheses are rejected using BH are supplied to Procedure 1 to identify clusters. The realized FDR*~s~* is defined as the average across 100 iterations of the fraction of falsely selected clusters over all clusters obtained.

![FDR*~s~* for the described procedures: in (A) we report results relative to EMMAX and in (B) relative to SMT. The dashed black line represents the target FDR*~s~* level of 0.05. Note that EMMAXs with $\rho = 1$ (*i.e.*, with no clustering) coincides with EMMAX, and that the FDR*~s~* for this specific case corresponds to the regular FDR. Shapes indicate the procedures: empty triangles for the application of BH to the collection of *P*-values from EMMAX for all hypotheses followed by clustering of the discoveries; filled triangles for the selective procedure EMMAXs; empty squares for the application of BH to the collection of *P*-values from SMTs for all hypotheses followed by clustering of the discoveries; filled squares for the selective procedure SMTs; and empty diamonds for the application of BH to the full collection of *P*-values with no clustering. Colors indicate the parameters for clustering: orange for $\rho = 0.3,$ turquoise for $\rho = 0.5,$ and blue for $\rho = 1.$](61fig3){#fig3}

[Figure 3](#fig3){ref-type="fig"} illustrates that, in agreement with Theorem 1, EMMAXs controls FDR*~s~* at all levels of *ρ* and for any number of causal SNPs. In contrast, BH applied to the full set of *P*-values obtained from EMMAX with *post hoc* clustering of the discoveries results in a somewhat elevated FDR*~s~* due to the deflation of the BH threshold. Moreover, EMMAXs offers better control of FDR*~s~* than SMTs, particularly as the number of causal SNPs increases. This makes sense given that EMMAX better accounts for the polygenic effects than the SMT.

### GeneSLOPE error control and power: {#s12}

[Figure 4](#fig4){ref-type="fig"} illustrates the performance of geneSLOPE in terms of FDR*~s~* and power in the context of the performance of EMMAXs and SMTs for the same setting and range of *k*. For all procedures, power decreases as *k* increases, with a slower decay for geneSLOPE. Note that the average power of geneSLOPE is systematically larger than the power of SMTs, with the difference increasing with *k*, while the FDR*~s~* of geneSLOPE is always smaller than that of SMTs. [Figure 4](#fig4){ref-type="fig"} also demonstrates how using the standard genome-wide significance threshold setting $\pi = 5 \times 10^{- 8}$ results in a very substantial loss of power as compared to procedures controlling FDR.

![(A) FDR*~s~* and (B) power for geneSLOPE. Clustering is done with $\pi = 0.05,$ $\rho = 0.3,$ and the target FDR*~s~* level 0.05 (marked with a dashed line). Values for geneSLOPE are in blue. For comparison, we reproduce from [Figure 3](#fig3){ref-type="fig"} the curves indicating the performance of EMMAXs and SMTs for the same setting (marked in shades of orange). We also include the values of (A) FDR*~s~* and (B) power when EMMAXs and SMTs are carried out using cluster representatives selected with $\pi = 5 \times 10^{- 8},$ the standard GWAS genome-wide significance threshold (marked in shades of purple). Shapes indicate the procedures: Filled circles for geneSLOPE, filled triangles for EMMAXs, and filled squares for SMTs.](61fig4){#fig4}

Real data analysis {#s13}
------------------

To analyze the lipid phenotypes, we adopted the protocol described in [@bib36]: subjects that had not fasted or were being treated for diabetes (*n* = 487) were excluded, leaving a set of $4915$ subjects for further analysis. All phenotypes were adjusted for sex, pregnancy, oral contraceptive use, and population structure as captured by the first five genotype principal components (computed using E[igensoft]{.smallcaps}, [@bib31]); the residuals were used as the trait values $Y_{i}$ in the subsequent association analysis.

We compare the results of geneSLOPE, EMMAXs, and classically applied EMMAX. GeneSLOPE (Procedure 1 followed by Procedure 3) was applied using $\pi = 0.05,$ *ρ* = 0.3 or 0.5, and *q* = 0.05 or 0.1 (for a total of four versions) to a centered and normalized version of the genotype matrix where each column has mean 0 and $\ell_{2}$ norm 1. EMMAXs (Procedure 1 followed by Procedure 2) was applied with $\pi = 0.05,$ *ρ* = 0.3 or 0.5, and *q* = 0.05 or 0.1. To mimic the standard GWAS analysis, we ran EMMAX identifying as significant those SNPs with *P*-value $\leq 5 \times 10^{- 8};$ to obtain comparable numbers of discovered SNPs we applied Procedure 1 to cluster the results.

We compare the discoveries of these three methods on the NFBC data to those reported in [@bib20]), a much more powerful study based on 188,577 subjects. We compute the realized selected false discovery proportion FDP*~s~* for each method assuming that SNPs within 1 Mb of a discovery (defined as *P* \< 5 × 10^−8^) in the comparison study are true positives (even if, of course, the biological truth for the given study population is not known, and the association statistics in [@bib20] are based on univariate tests and may therefore not fully capture the genetic underpinnings of these complex traits). We also seek to understand what proportion of the trait heritability is captured by the selected SNPs. To this end, we estimate the proportion of phenotypic variance explained by the set of genome-wide autosomal SNPs using Genome-wide Complex Trait Analysis (GCTA) ([@bib47]), and compare this to the adjusted $r^{2}$ obtained from a multiple regression model including the selected cluster representatives as predictors.

The estimated proportion of phenotypic variance explained by genome-wide SNPs is 0.34, 0.32, 0.10, and 0.29 for HDL, LDL, TG, and CHOL, respectively. A comparison of the number of discoveries (*i.e.*, the number of selected cluster representatives), number of true discoveries, FDP*~s~*, and $r^{2}$ across methods is given in [Figure 5](#fig5){ref-type="fig"}. As an illustrative example, geneSLOPE selections with *π* = 0.05, *q* = 0.1, and *ρ* = 0.5 are shown in [Figure 6](#fig6){ref-type="fig"} along with *P*-values obtained using EMMAX and those obtained in the more highly powered comparison study ([@bib20]).

![Study of four lipid traits. Comparison of results for HDL, LDL, TG, and CHOL. "Number of discoveries" corresponds to the number of selected cluster representatives under each method; true and false discoveries are marked in green and red, respectively. FDP~s~ is the realized selected false discovery proportion, and $r^{2}/h^{2}$ is the adjusted $r^{2}$ obtained when using the set of selected cluster representatives as predictors in a multiple regression model divided by the proportion of phenotype variance explained by genome-wide SNPs obtained using GCTA.](61fig5){#fig5}

![Localization of lipid signals. GeneSLOPE selections using $\pi = 0.05,$ *ρ* = 0.5, and target FDR~s~ 0.1 are marked using solid green bars for cluster representatives and semitransparent bars for the remaining members of the cluster. *P*-values from EMMAX (purple) and the Global Lipids Genetics Consortium comparison study (orange) are plotted on the −log10 scale. The horizontal dashed line marks a significance cut off of 5 × 10^−8^, and the purple diamonds below the *x*-axis represents selected cluster representatives under EMMAX using $\pi = 0.05,$ $\rho = 0.3,$ and a *P*-value threshold of 5 × 10^−8^.](61fig6){#fig6}

The application on real data illustrates how FDR*~s~* controlling procedures are more powerful than the standard practice of identifying significant SNPs using a *P*-value threshold of $5 \times 10^{- 8}.$ Both EMMAXs and geneSLOPE attain realized selected false discovery proportions that are consistent with the nominal targeted FDR*~s~*. There does not appear to be a power advantage of multiple linear regression (geneSLOPE) over univariate tests (EMMAXs) in this example. This is consistent with the results in our simulations, which indicate that multivariate analysis is really more powerful when there are many (detectable) signals contributing to the phenotype. While it is by now established that 100s of different loci contribute to lipid levels, the signal strength in our data set (which has a modest sample size) is such that only a handful can be identified. In this regime, we find no evidence of an increased power for the multiple linear model. However, this data analysis also shows the potential advantage on the multivariate methods with respect to signal resolution. Changing the value of *ρ* from 0.3 to 0.5 had a negligible influence on the number of discoveries made by geneSLOPE but substantially increased the number of discoveries by EMMAXs. This suggests that some of the clusters corresponding to $\rho = 0.3$ were split into smaller clusters for $\rho = 0.5,$ and that in the case of SMT, the resolution of $\rho = 0.5$ is not sufficient to prevent representing one biological discovery by two or more clusters. This observation goes along with the simulation results reported in the previous section.

Discussion {#s14}
==========

Following up on an initial suggestion by [@bib37] and reflecting on the elements of the standard practice, we argue that discoveries in a GWAS study should not be counted in terms of the number of SNPs for which the hypothesis of no association is rejected, but in terms of the number of clusters of such SNPs. We propose a strategy to control the FDR of these discoveries that consists in identifying groups of hypotheses on the basis of the observed data, selecting a representative for each group, and applying a modified FDR-controlling procedure to the *P*-values for the selected hypotheses. We present two articulations of this strategy: in one case we rely on marginal tests of association and modify the target rate of BH on the selected hypotheses, and in the other case we build on our previous work on SLOPE to fit a multiple linear regression model. We show with simulations and real data analysis that the suggested approaches appear to control FDR*~s~* and allow an increase in power with respect to the standard analysis methods for GWAS.

The idea of identifying groups of hypotheses and somehow transferring the burden of FDR control from the single hypothesis level to a group one is not new ([@bib29]; [@bib5]). In particular, two recent contributions to the literature can be considered parallel to our suggestions. In the context of tests for marginal association, [@bib18] propose a methodology to control FDR both at the level of single hypotheses and groups. In the context of multiple regression, [@bib11] extend SLOPE to control the FDR for the discoveries of groups of predictors. Both these contributions, however, are substantially different from ours in that they require a definition of groups prior to observation of the data. Instead, our clusters are adaptive to the signal, and are identified starting from the data. This assures that the group of hypotheses are centered around the locations with strongest signal.

Defining cluster representatives that are input into a multiple regression framework allows us to think more carefully about what FDR means in the context of a regression model that does not include among the regressor the true causal variants; where one is substantially looking for relevant proxies. In their recent work, [@bib17] take a different approach, deciding to focus on the directional FDR. The knock-off filter provides an attractive methodology to analyze GWAS data. However, it still requires an initial selection step: top performance can be achieved only when the selected features are optimally capturing the signal present in a given data set. We believe that the cluster-representatives approach has a substantial edge at this level over, for example, running lasso with only a modest penalization parameter.

Here, we consider a fairly simple strategy to construct clusters of SNPs, exploring two possible levels of resolution corresponding to $\rho = 0.3$ and $\rho = 0.5.$ In reality, depending on sample size and genotype density, each data set might have a different achievable level of resolution. The study of how this can be adaptively learned is deferred to future work.

It should be noted that while we conduct formal testing only on the selected set of cluster representatives, when the null hypothesis of no association is rejected for a selected SNP, the entire cluster is implicated. In other words, in follow-up studies, the entire region spanned by the cluster should be considered associated with the trait in question. This is entirely similar to what is standard practice after localizing association to a region: all variants in LD with the signal are implicated, and to sort through them, multiple regression models are employed ([@bib24]).

It is common practice in GWAS studies to rely on the imputation of untyped SNPs to augment the power to detect association. In this context, a cluster should be formed using both the typed and imputed SNPs, so that representatives with maximal power might be selected. The adjusted thresholds for significance (or the penalization coefficients in the case of SLOPE), however, should be determined on the basis of the number of typed SNPs only; since this defines the degrees of freedom of the problem.

Finally, we would like to underscore how, even if we have focused on the case of GWAS here, adopting a selective approach might have wide range applications whenever there is not an exact correspondence between the hypotheses conveniently tested and the granularity of the scientific discoveries. Further studies of the emerging literature on selective inference should lead to better understanding of the theoretical properties of the method we propose, as well as to the identification of other possible strategies.
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Throughout, *R* is the number of rejections the two-step procedure commits. Note that the critical values for the BH procedure after selection are of the form $q_{k} = {{qk}/M}.$

By definition, letting $\mathcal{H}_{0}$ of cardinality $M_{0}$ be the set of nulls,$$\text{FDR} = \mathbb{E}\left( \frac{\sum_{i \in \mathcal{H}_{0}}{1\left\{ {H_{i}\,\text{rejected}} \right\}}}{\text{max}\left\{ {1,R} \right\}} \right).$$Setting $V_{i} = 1\left\{ {H_{i}\,\text{rejected}} \right\},$ we have that for all $i \in \mathcal{H}_{0},$$$\begin{matrix}
{\mathbb{E}\left( \frac{V_{i}}{\text{max}\left\{ {1,R} \right\}} \right) = {\sum\limits_{k = 1}^{M}{\mathbb{E}\left( \frac{1\left\{ {i \in S\,\text{and}\, p_{i} \leq q_{k}} \right\}\, 1\left\{ {R = k} \right\}}{k} \right)}}} \\
{\leq {\sum\limits_{k = 1}^{M}{\mathbb{E}\left( \frac{1\left\{ {p_{i} \leq q_{k}} \right\}\, 1\left\{ {R = k} \right\}}{k} \right)}}} \\
{= \frac{q}{M}{\sum\limits_{k = 1}^{M}\frac{{\mathbb{P}}\left( {R = k\,\text{and}\, p_{i} \leq q_{k}} \right)}{{\mathbb{P}}\left( {p_{i} \leq q_{k}} \right)}}} \\
{= \frac{q}{M}{\sum\limits_{k = 1}^{M}{{\mathbb{P}}\left( {\left. {R = k} \right|p_{i} \leq q_{k}} \right)}}.} \\
\end{matrix}$$The calculation is now as in [@bib7]. The key observation is that since $1\left\{ {R \leq k} \right\}$ is an increasing set, we have$${\mathbb{P}}\left( {\left. {R \leq k} \right|p_{i} \leq q_{k}} \right) \leq {\mathbb{P}}\left( {\left. {R \leq k} \right|p_{i} \leq q_{k + 1}} \right).$$So consider the first two terms of the sum (4):$$\begin{matrix}
{{\mathbb{P}}\left( {\left. {R \leq 1} \right|p_{i} \leq q_{1}} \right) + {\mathbb{P}}\left( {\left. {R = 2} \right|p_{i} \leq q_{2}} \right) \leq {\mathbb{P}}\left( {\left. {R \leq 1} \right|p_{i} \leq q_{2}} \right) + {\mathbb{P}}\left( {\left. {R = 2} \right|p_{i} \leq q_{2}} \right)} \\
{= {\mathbb{P}}\left( {\left. {R \leq 2} \right|p_{i} \leq q_{2}} \right).} \\
\end{matrix}$$Continuing in this fashion, we have that$${\sum\limits_{k = 1}^{M}{{\mathbb{P}}\left( {\left. {R = k} \right|p_{i} \leq q_{k}} \right) \leq {\mathbb{P}}\left( {\left. {R \leq M} \right|p_{i} \leq q_{M}} \right)}} = 1.$$Hence, for each $i \in \mathcal{H}_{0},$$$\left. \mathbb{E}\left( \frac{V_{i}}{\max\left\{ {1,R} \right\}} \right) \leq {q/M}\quad\Rightarrow\quad{FDR} \leq {{qM_{0}}/M}. \right.$$*Remark:* Under independence, we know that if we select everything, *i.e.*, $S = \left\{ {1,\ldots,M} \right\}$ almost surely, then $\mathit{FDR} = {{qM_{0}}/M}.$ Here, when we select less while retaining the monotonicity assumption, it is possible to have an FDR less than ${{qM_{0}}/M}.$ $\square$

***Procedure 4*.** *Sequence of penalties λ for SLOPE*.

*Input:* $q \in \left( {0,1} \right);$ $n,M \in {\mathbb{N}}$

1.  set $\lambda_{BH} = \left\lbrack {\lambda_{BH}\left( 1 \right),\ldots,\lambda_{BH}\left( M \right)} \right\rbrack^{T},$ for $\lambda_{BH}\left( i \right) = \Phi^{- 1}\left( {1 - \frac{qi}{2M}} \right);$

2.  define$$\lambda_{G}\left( i \right) = \begin{cases}
    {\lambda_{BH}\left( 1 \right),} & {i = 1} \\
    {\lambda_{BH}\left( i \right)\sqrt{1 + {\sum_{j < i}\frac{\lambda_{G}^{2}\left( j \right)}{n - i}}},} & {i = 1} \\
    \end{cases};$$

3.  find the largest index, $k^{\star},$ such that $\lambda_{G}\left( 1 \right) \geq \ldots \geq \lambda_{G}\left( k^{\star} \right);$

4.  put$$\lambda_{i} = \left\{ \begin{matrix}
    {\lambda_{G}\left( i \right),} & {i \leq k^{\star}} \\
    {\lambda_{G}\left( k^{\star} \right),} & {i = k^{\star}} \\
    \end{matrix} \right..$$

***Procedure 5*.** *Selecting λ when σ is unknown.*

*Input:* *y*, *X*, and basic sequence *λ*

1.  initialize:$S_{+} = \varnothing$

And repeat

1.  $S = S_{+}$

2.  compute RSS obtained by regressing *y* onto variables in *S*

3.  set ${\hat{\sigma}}^{2} = {{RSS}/\left( {n - \left| S \right| - 1} \right)},$ where \|S\| is the number of elements in S

4.  compute the solution $\overset{\sim}{\beta}$ to SLOPE with parameter sequence $\overset{\sim}{\sigma} \cdot \lambda_{S}$

5.  set $S_{+} = supp\left( \overset{\sim}{\beta} \right)$ (*i.e.*, $S_{+}$ is the set of regressors selected by SLOPE in step 5).

until $S_{+} = S$
